Literature DB >> 23695002

[Schizophrenia - a disorder in its own right?: results from 25 years of the ABC study].

H Häfner1, K Maurer, W An der Heiden.   

Abstract

BACKGROUND: The ABC schizophrenia study conducted by the same team over 25 years initially aimed at illuminating the onset, prodromal stage and sex differences in age at first hospitalization in schizophrenia. New hypotheses were systematically generated from the results achieved.
METHODS: A population-based sample of 276 first admission cases (232 first episodes, age 12-59 years), including a subsample of 130 first admissions (115 first episodes), were assessed to study prodromal stage, first illness episode, medium and long-term course and symptom dimensions in schizophrenia. The samples were compared with age and sex-matched healthy controls and with patients first admitted for unipolar depression. A total of 1,109 consecutive first admissions for schizophrenia spectrum disorders independent from the other study samples were assessed to study changes in symptomatology across the age range.
RESULTS: Before the onset of psychotic symptoms the prodromal stages of schizophrenia and severe and moderately severe depression are difficult to distinguish. The most frequent symptom in the course of schizophrenia, depressed mood, also represents the most frequent initial symptom in both disorders. Prodromal depression is a predictor of more depressive and positive symptoms in the first episode but not in the further course of the illness. Psychosis incidence for men, diagnosed according to ICD 9 (295, 297, 298.3/4), shows a pronounced peak at age 15-24 years, for women a lower peak at age 15-29 years and a second, still lower peak at the menopausal age of 45-49 years. The explanation, confirmed in animal experiments, lies in a protective effect of estrogen due to reduced D2 receptor sensitivity. The effect is antagonized by an elevated genetic risk. Functional and social impairment emerge even at the prodromal stage and the severity depends on sex and social status. Young men with schizophrenia show a less favorable social course because of the earlier age of onset and socially adverse illness behavior. Late onset is associated with a milder, primarily paranoid symptomatology and less severe social impairment. Schizophrenia is a disorder of all ages showing roughly equal life time incidence rates for men and women but considerable difference in certain periods of age. The symptom dimensions show a plateau-like course 2-5 years after the first episode. Hidden behind this picture are irregular symptom exacerbations which vary in duration. Schizophrenia conveys the picture of recurrent vulnerability to crisis and not of a stable residual state of disordered brain development or of a progressive neurodegenerative process.

Entities:  

Mesh:

Year:  2013        PMID: 23695002     DOI: 10.1007/s00115-013-3788-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  27 in total

1.  Association between age at onset and clinical features of schizophrenia: the Northern Finland 1966 birth cohort study.

Authors:  Suvi Luoma; Helinä Hakko; Taru Ollinen; Marjo-Riitta Järvelin; Sari Lindeman
Journal:  Eur Psychiatry       Date:  2008-05-02       Impact factor: 5.361

2.  How does gender influence age at first hospitalization for schizophrenia? A transnational case register study.

Authors:  H Häfner; A Riecher; K Maurer; W Löffler; P Munk-Jørgensen; E Strömgren
Journal:  Psychol Med       Date:  1989-11       Impact factor: 7.723

3.  Is schizophrenia a disorder of all ages? A comparison of first episodes and early course across the life-cycle.

Authors:  H Häfner; M Hambrecht; W Löffler; P Munk-Jørgensen; A Riecher-Rössler
Journal:  Psychol Med       Date:  1998-03       Impact factor: 7.723

Review 4.  Gender differences in age at onset of schizophrenia. An overview.

Authors:  M C Angermeyer; L Kühn
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988-09

5.  Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial.

Authors:  Shahin Akhondzadeh; Ali Akbar Nejatisafa; Homayoun Amini; Mohammad Reza Mohammadi; Bagher Larijani; Ladan Kashani; Firoozeh Raisi; Abbas Kamalipour
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-09       Impact factor: 5.067

6.  [Schizophrenia and delusions in middle aged and elderly patients. Epidemiology and etiological hypothesis].

Authors:  H Häfner; W Löffler; A Riecher-Rössler; W Häfner-Ranabauer
Journal:  Nervenarzt       Date:  2001-05       Impact factor: 1.214

7.  Main risk factors for schizophrenia: increased familial loading and pre- and peri-natal complications antagonize the protective effect of oestrogen in women.

Authors:  R Könnecke; H Häfner; K Maurer; W Löffler; W an der Heiden
Journal:  Schizophr Res       Date:  2000-07-07       Impact factor: 4.939

8.  The ABC Schizophrenia Study: a preliminary overview of the results.

Authors:  H Häfner; K Maurer; W Löffler; W an der Heiden; P Munk-Jørgensen; M Hambrecht; A Riecher-Rössler
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1998-08       Impact factor: 4.328

9.  [Sex differences in schizophrenic diseases].

Authors:  H Häfner; A Riecher; K Maurer; B Fätkenheuer; W Löffler; W an der Heiden; P Munk-Jørgensen; E Strömgren
Journal:  Fortschr Neurol Psychiatr       Date:  1991-09       Impact factor: 0.752

10.  Validation of Danish case register diagnosis for schizophrenia.

Authors:  W Löffler; H Häfner; B Fätkenheuer; K Maurer; A Riecher-Rössler; J Lützhøft; S Skadhede; P Munk-Jørgensen; E Strömgren
Journal:  Acta Psychiatr Scand       Date:  1994-09       Impact factor: 6.392

View more
  6 in total

Review 1.  [Long-term treatment of schizophrenia spectrum disorders: focus on pharmacotherapy].

Authors:  L Deutschenbaur; M Lambert; M Walter; D Naber; C G Huber
Journal:  Nervenarzt       Date:  2014-03       Impact factor: 1.214

2.  Psychiatric Diagnoses and Treatment Preceding Schizophrenia in Adolescents Aged 9-17 Years.

Authors:  Christina D Kang-Yi; Brian Chao; Shelly Teng; Jill Locke; David S Mandell; Yin-Ling Irene Wong; C Neill Epperson
Journal:  Front Psychiatry       Date:  2020-06-04       Impact factor: 4.157

3.  Reduction of Involuntary Admissions in Patients With Severe Psychotic Disorders Treated in the ACCESS Integrated Care Model Including Therapeutic Assertive Community Treatment.

Authors:  Daniel Schöttle; Friederike Ruppelt; Benno G Schimmelmann; Anne Karow; Alexandra Bussopulos; Jürgen Gallinat; Klaus Wiedemann; Daniel Luedecke; Anja Christine Rohenkohl; Christian G Huber; Thomas Bock; Martin Lambert
Journal:  Front Psychiatry       Date:  2019-10-24       Impact factor: 4.157

Review 4.  Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models.

Authors:  James N Samsom; Albert H C Wong
Journal:  Front Psychiatry       Date:  2015-02-18       Impact factor: 4.157

5.  Effectiveness of integrated care including therapeutic assertive community treatment in severe schizophrenia-spectrum and bipolar I disorders: Four-year follow-up of the ACCESS II study.

Authors:  Daniel Schöttle; Benno G Schimmelmann; Friederike Ruppelt; Alexandra Bussopulos; Marietta Frieling; Evangelia Nika; Luise Antonia Nawara; Dietmar Golks; Andrea Kerstan; Matthias Lange; Michael Schödlbauer; Anne Daubmann; Karl Wegscheider; Anja Rohenkohl; Gizem Sarikaya; Mary Sengutta; Daniel Luedecke; Linus Wittmann; Gunda Ohm; Christina Meigel-Schleiff; Jürgen Gallinat; Klaus Wiedemann; Thomas Bock; Anne Karow; Martin Lambert
Journal:  PLoS One       Date:  2018-02-27       Impact factor: 3.240

Review 6.  Genetic Predisposition to Schizophrenia and Depressive Disorder Comorbidity.

Authors:  Natalia A Shnayder; Maxim A Novitsky; Nikolay G Neznanov; Oleg V Limankin; Azat R Asadullin; Artem V Petrov; Diana V Dmitrenko; Ekaterina A Narodova; Natalia V Popenko; Regina F Nasyrova
Journal:  Genes (Basel)       Date:  2022-03-02       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.